scispace - formally typeset
Search or ask a question
Author

Jianping Liu

Bio: Jianping Liu is an academic researcher from China Pharmaceutical University. The author has contributed to research in topics: Medicine & Drug delivery. The author has an hindex of 24, co-authored 99 publications receiving 1975 citations.


Papers
More filters
Journal ArticleDOI
TL;DR: In this review, the advantages of lipid-based nanocarriers as non-invasive topical ocular drug delivery systems are presented and many systems, including emulsions, liposome, cubosomes, niosomes and other lipid- based nanoccarriers are reviewed.

214 citations

Journal ArticleDOI
TL;DR: Results of studies showed that microemulsion system of theophylline might be promising vehicles for the transdermal delivery of thephylline.

131 citations

Journal ArticleDOI
TL;DR: In this article, the central composite rotatable design (CCRD) model was used to optimize formulations of dihydroartemisinin nancistructured lipid carrier (DHA-NLC).

112 citations

Journal ArticleDOI
TL;DR: A hyaluronan (HA)-modified core-shell liponanoparticles (HA-LCS-NPs) was designed to improve the treatment efficiency by increasing RPE-targeted distribution and prolonged intraocular residence.

76 citations

Journal ArticleDOI
TL;DR: In this paper, Discoidal and spherical recombinant HDL loaded with cardiovascular drug tanshinone IIA (TA) were constructed (TA-d-rHDL and TA-s-RHDL), and their in vitro physiochemical and biomimetic properties were characterized.

71 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: Bhushan S. Pattni,† Vladimir V. Chupin,‡ and Vladimir P. Torchilin study the role of phosphorous in the biosynthesis of Membrane Proteins and found that phosphorous binds to polypeptide A in a manner similar to that of polymethine.
Abstract: Bhushan S. Pattni,† Vladimir V. Chupin,‡ and Vladimir P. Torchilin*,†,§,∥ †Department of Pharmaceutical Sciences, Center for Pharmaceutical Biotechnology and Nanomedicine, Northeastern University, Boston, Massachusetts 02115, United States ‡Laboratory for Advanced Studies of Membrane Proteins, Moscow Institute of Physics and Technology, Dolgoprudny 141700, Russia Department of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia

1,124 citations

Journal ArticleDOI
TL;DR: It became clear that many of the treatments available for the management of dry eye disease lack the necessary Level 1 evidence to support their recommendation, often due to a lack of appropriate masking, randomization or controls and in some cases due to issues with selection bias or inadequate sample size.
Abstract: The members of the Management and Therapy Subcommittee undertook an evidence-based review of current dry eye therapies and management options. Management options reviewed in detail included treatments for tear insufficiency and lid abnormalities, as well as anti-inflammatory medications, surgical approaches, dietary modifications, environmental considerations and complementary therapies. Following this extensive review it became clear that many of the treatments available for the management of dry eye disease lack the necessary Level 1 evidence to support their recommendation, often due to a lack of appropriate masking, randomization or controls and in some cases due to issues with selection bias or inadequate sample size. Reflecting on all available evidence, a staged management algorithm was derived that presents a step-wise approach to implementing the various management and therapeutic options according to disease severity. While this exercise indicated that differentiating between aqueous-deficient and evaporative dry eye disease was critical in selecting the most appropriate management strategy, it also highlighted challenges, based on the limited evidence currently available, in predicting relative benefits of specific management options, in managing the two dry eye disease subtypes. Further evidence is required to support the introduction, and continued use, of many of the treatment options currently available to manage dry eye disease, as well as to inform appropriate treatment starting points and understand treatment specificity in relation to dry eye disease subtype.

785 citations

Journal ArticleDOI
TL;DR: P pH-responsive biomaterials bring forth conformational changes in these nanocarriers through various mechanisms such as protonation, charge reversal or cleavage of a chemical bond, facilitating tumour specific cell uptake or drug release, helping to design more efficient drug delivery systems.

698 citations

Journal ArticleDOI
TL;DR: In this review, beneficial aspects of NLC are presented and valuable information about ingredients, production methods, structure and characteristics of them provided, and potential applications and disadvantages of N LC as emerging delivery system in food science are introduced.
Abstract: Particle size and physical state of the lipid phase are major factors influencing the permanence of lipid dispersions. Nanostructured lipid carriers (NLC) are a delivery system in which partial-crystallized lipid particles with mean radii ≤ 100 nm are dispersed in an aqueous phase containing emulsifier(s), as a potential delivery system may have some advantages in certain circumstances when compared with other colloidal carriers. NLC are a useful nutraceutical delivery system with high drug loading, encapsulation efficiency and stability. They may increase, bioavailability and stability of bioactive compounds, and shelf-life, consumer acceptability, functionality, nutritional value and safety of food systems, and provide controlled release of encapsulated materials. In this review, beneficial aspects of NLC are presented and valuable information about ingredients, production methods, structure and characteristics of them provided. Moreover, potential applications and disadvantages of NLC as emerging delivery system in food science are introduced. Industrial relevance With the increasing public perception of a strong correlation between food and disease prevention, producers are trying to enrich staple foods and beverages with nutraceuticals and produce functional foods. Nonetheless, fortification of aqueous-based food with many of nutraceuticals is greatly limited owing to their poor water-solubility, chemical instability, and low bioavailability. NLC are a novel nanocarrier that may dispel these limitations, combine the advantages of other lipid nanocarriers and avoid some of their disadvantages. They may be suitable for application within foods and transparent/opaque beverages.

479 citations

Journal ArticleDOI
TL;DR: The understanding of the nanostructured lipid carriers (NLC)-based formulations has improved with continuing research recently, and the result has seen an increase in the use of these in the clinical setting.

460 citations